Life Sciences Insight

Stefan Wolf appointed CEO of Binding Site

Former CEO, Charles de Rohan, to retire and join Board of Directors

The Board of Directors of The Binding Site (“TBS” or “the Company”) is pleased to announce the appointment of Stefan Wolf as CEO of the Company. Stefan was until recently the Global Division President running both the Clinical Diagnostic and Immunodiagnostic divisions of Thermo Fisher Scientific. Charles de Rohan will remain part of The Binding Site ecosystem through his membership on the Board of Directors.

Carl Hull, Chairman of the Board, commented: “We are delighted to bring someone of Stefan’s caliber to The Binding Site. Stefan has spent his entire career of over 30 years in the In Vitro Diagnostics industry, including his most recent senior leadership role at Thermo Fisher Scientific. His experience and international profile are valuable assets to TBS – both will allow him to leverage the Company’s demonstrable science-based culture to accelerate TBS’s track record of innovative growth. I fully understand and support Charles’s request to move to an advisory role after ten years with TBS, and I am very happy that we will retain his experience on the Board.”

Stefan Wolf, noted: “I have followed The Binding Site story for many years and have been impressed by the Company’s ability to harness its deep scientific knowledge, particularly in the field of complex proteins. This is demonstrated by the Company’s development of the Freelite assay into the gold standard clinical benchmark for diagnosis and monitoring of myeloma and related disorders. I am looking forward to working with the Company’s many talented and passionate colleagues to build upon the foundation that Charles and his team have so effectively established to date.”

Since its founding by researchers at the University of Birmingham in 1983, The Binding Site has continued to build on its strong scientific foundations, supporting research and development within its field and responding to the changing needs of patients, researchers and clinicians for over 35 years. TBS has consistently delivered a high double-digit organic growth rate, with over 3,600 high impact scientific publications. Today, the business is a global, commercial leader in the immunodiagnostic space with an installed base of over 1,200 instruments around the world. The Company’s employees are singularly dedicated to improving patient lives, by delivering innovative medical solutions that improve the diagnosis and management of blood cancers and immune system disorders.

Charles de Rohan, former CEO, said: “I am extremely proud of the achievements of the entire TBS team over the last decade. Our products are best-in-class with respect to value to our lab customers – a position that is directly attributable to the patient-centric and science-driven ethos that has defined TBS from the day it was founded. We have been and will continue to be grateful to the key opinion leaders in immunodiagnostics across the world who have been a source of inspiration and support for the Company’s researchers. I am delighted that Stefan will take over as CEO and am convinced that he will be a terrific leader for The Binding Site. This is a company full of very talented colleagues, and I very much look forward to continue assisting as a member of the Board of Directors.”

Jonas Agnblad, Partner and Co-Head of Healthcare,
 Nordic Capital Advisors, and Javed Khan, Co-Managing Partner of Five Arrows Principal Investments, both members of the Board, added: “We believe that Stefan is the right person to lead the business as the Company begins commercialising its exciting, patented innovations to substantially expand its product offering. TBS’s addressable market is primed for a step change in the coming years, as its Mass Spectrometry product range is launched around the world. The width and depth of The Binding Site’s technology bench is impressive by all standards, and we are confident that the Company’s new product pipeline will cement its position in existing therapeutic areas as well as expand into new indications – within oncology and other protein-linked disorders. TBS has delivered a decade of consistent and impressive growth under Charles’s leadership, for which we are extremely grateful. We wish him the best of luck as he begins his retirement and are looking forward to continue working with him in his capacity as a board member.”